AFT Pharmaceuticals says decision imminent on dual listing in NZ, Australia

AFT Pharmaceuticals says decision imminent on dual listing in NZ, Australia
Fiona Rotherham
By Fiona Rotherham Oct. 2 (BusinessDesk) - AFT Pharmaceuticals, a drugs developer and reseller,  has confirmed it’s close to making a final decision on a share-market listing first mooted in May. The Australian Financial Review's Street Talk column reported today that the Kiwi firm had kicked off informal investor briefings for a dual listing on the NZX and ASX, with First NZ Capital as an adviser and a value of $200 million to $300 million. AFT founder and majority shareholder Hartley Atkinson denied the reported valuation of the company...